346 related articles for article (PubMed ID: 23605142)
1. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.
Qi WX; Tang LN; He AN; Yao Y; Shen Z
Int J Clin Oncol; 2014 Apr; 19(2):403-10. PubMed ID: 23605142
[TBL] [Abstract][Full Text] [Related]
2. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.
Boquete-Castro A; Gómez-Moreno G; Calvo-Guirado JL; Aguilar-Salvatierra A; Delgado-Ruiz RA
Clin Oral Implants Res; 2016 Mar; 27(3):367-75. PubMed ID: 25639776
[TBL] [Abstract][Full Text] [Related]
3. Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis.
Zhang C; Shen G; Li H; Xin Y; Shi M; Zheng Y; Wang M; Liu Z; Zhao Y; Zhao F; Ren D; Zhao J
Spec Care Dentist; 2024; 44(2):530-541. PubMed ID: 37219080
[TBL] [Abstract][Full Text] [Related]
4. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?
Van den Wyngaert T; Wouters K; Huizing MT; Vermorken JB
Support Care Cancer; 2011 Dec; 19(12):2035-40. PubMed ID: 21203781
[TBL] [Abstract][Full Text] [Related]
5. Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.
O'Halloran M; Boyd NM; Smith A
Aust Dent J; 2014 Dec; 59(4):516-9. PubMed ID: 25131835
[TBL] [Abstract][Full Text] [Related]
6. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
Sivolella S; Lumachi F; Stellini E; Favero L
Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.
Owosho AA; Blanchard A; Levi L; Kadempour A; Rosenberg H; Yom SK; Farooki A; Fornier M; Huryn JM; Estilo CL
J Craniomaxillofac Surg; 2016 Mar; 44(3):265-70. PubMed ID: 26782845
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies.
Qi WX; Lin F; He AN; Tang LN; Shen Z; Yao Y
Curr Med Res Opin; 2013 Sep; 29(9):1067-73. PubMed ID: 23745518
[TBL] [Abstract][Full Text] [Related]
10. Denosumab-related osteonecrosis of the jaw.
Diz P; López-Cedrún JL; Arenaz J; Scully C
J Am Dent Assoc; 2012 Sep; 143(9):981-4. PubMed ID: 22942143
[TBL] [Abstract][Full Text] [Related]
11. Review of current literature and implications of RANKL inhibitors for oral health care providers.
Epstein MS; Ephros HD; Epstein JB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Dec; 116(6):e437-42. PubMed ID: 22901640
[TBL] [Abstract][Full Text] [Related]
12. Antiresorptive drug-related osteonecrosis of the jaw.
Uyanne J; Calhoun CC; Le AD
Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
[TBL] [Abstract][Full Text] [Related]
13. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw.
Troeltzsch M; Woodlock T; Kriegelstein S; Steiner T; Messlinger K; Troeltzsch M
J Can Dent Assoc; 2012; 78():c85. PubMed ID: 22985897
[TBL] [Abstract][Full Text] [Related]
14. Stage 0 osteonecrosis of the jaw in a patient on denosumab.
Aghaloo TL; Dry SM; Mallya S; Tetradis S
J Oral Maxillofac Surg; 2014 Apr; 72(4):702-16. PubMed ID: 24397946
[TBL] [Abstract][Full Text] [Related]
15. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
16. Denosumab-associated osteonecrosis of the jaw--a case report.
Vyas S; Hameed S; Murugaraj V
Dent Update; 2014 Jun; 41(5):449-50. PubMed ID: 25073227
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the jaw.
Drozdzowska B
Endokrynol Pol; 2011; 62(1):88-92. PubMed ID: 21365586
[TBL] [Abstract][Full Text] [Related]
18. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
[TBL] [Abstract][Full Text] [Related]
20. Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review.
de Boissieu P; Kanagaratnam L; Mahmoudi R; Morel A; Dramé M; Trenque T
Eur J Clin Pharmacol; 2017 May; 73(5):517-523. PubMed ID: 28188332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
